272 related articles for article (PubMed ID: 35217902)
21.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
22. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
23. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
[TBL] [Abstract][Full Text] [Related]
24. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
25. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
[TBL] [Abstract][Full Text] [Related]
26. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
[TBL] [Abstract][Full Text] [Related]
27. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
28. Rapid Tumor Washout of 177 Lu-PSMA Radioligand in Renal Cell Carcinoma.
Zhang J; Schuchardt C; Chen X; Baum RP
Clin Nucl Med; 2023 Aug; 48(8):732-734. PubMed ID: 37276536
[TBL] [Abstract][Full Text] [Related]
29. Pituitary Metastasis of Renal Cell Carcinoma Characterized by 18F-Prostate-Specific Membrane Antigen-1007 PET/CT.
Tariq A; Raman V; Alexander H; Roberts MJ; Thomas P
Clin Nucl Med; 2022 Apr; 47(4):e346-e347. PubMed ID: 35044961
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.
Yin Q; Xu H; Zhong Y; Ni J; Hu S
BMC Cancer; 2022 Feb; 22(1):163. PubMed ID: 35148700
[TBL] [Abstract][Full Text] [Related]
31. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
[TBL] [Abstract][Full Text] [Related]
34. Comparison of
Ling SW; de Jong AC; Schoots IG; Nasserinejad K; Busstra MB; van der Veldt AAM; Brabander T
Eur Urol Open Sci; 2021 Nov; 33():61-71. PubMed ID: 34632423
[TBL] [Abstract][Full Text] [Related]
35. The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential.
Urso L; Bauckneht M; Albano D; Chondrogiannis S; Grassetto G; Lanfranchi F; Dondi F; Fornarini G; Lazzeri M; Evangelista L
Expert Rev Med Devices; 2024; 21(1-2):55-72. PubMed ID: 38072680
[TBL] [Abstract][Full Text] [Related]
36. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
37. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Ferraro DA; Burger IA
Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
39. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
[TBL] [Abstract][Full Text] [Related]
40. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
